JP Morgan Maintains Overweight on Edgewise Therapeutics, Raises Price Target to $69

Benzinga · 1d ago
JP Morgan analyst Tessa Romero maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Overweight and raises the price target from $60 to $69.